Evaluation of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, by Skin Testing.
Phase of Trial: Phase I/II
Latest Information Update: 22 Dec 2015
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Grass pollen hypersensitivity
- Focus Therapeutic Use
- Sponsors Biomay
- 17 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 May 2011 New trial record